Trials / Active Not Recruiting
Active Not RecruitingNCT04489771
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 154 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that the higher dose of belzutifan is superior to the standard dose in terms of objective response rate (ORR).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Belzutifan | Oral administration |
Timeline
- Start date
- 2020-09-13
- Primary completion
- 2023-02-10
- Completion
- 2026-10-04
- First posted
- 2020-07-28
- Last updated
- 2025-02-11
- Results posted
- 2024-02-28
Locations
48 sites across 9 countries: United States, Australia, Belgium, Greece, Ireland, Israel, Netherlands, Russia, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04489771. Inclusion in this directory is not an endorsement.